In patients with HCL who develop resistance to first-line therapy with the purine analog 2-chloro-2′-deoxyadenosine [2-CdA] (cladribine), the use of BRAF inhibitor therapy is the standard of care. Here, BRAF is linked to hairy cell leukemia.